PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27655493-12	2016	Vascular remodeling in small and moderately sized pulmonary arteries was attenuated markedly in group B compared with group C. These results suggest that rosuvastatin can ameliorate the remodeling of pulmonary arteries in MCT-induced PAH rats by increasing the number of circulating EPCs and eNOS upregulation.	Rosuvastatin Calcium	154-166	nitric oxide synthase 3	Rattus norvegicus	292-296	
25881486-5	2015	Moreover, in aortic rings from rats with a CAF diet, rosuvastatin enhanced the expression of eNOS, inducible nitric oxide synthase, constitutive cyclooxygenase, and inducible cyclooxygenase.	Rosuvastatin Calcium	53-65	nitric oxide synthase 3	Rattus norvegicus	93-97	
26853250-6	2016	RESULTS: Compared with the TNF-alpha group, NO production, eNOS activity, and eNOS protein expression in the rosuvastatin, and yellow wine 1.0%, and 1.5% groups were significantly increased.	Rosuvastatin Calcium	109-121	nitric oxide synthase 3	Rattus norvegicus	78-82	
25524396-8	2015	In addition, the expression levels of VEGF, and Akt and eNOS phosphorylation were significantly higher in the group exposed to the combination treatment than in the group treated with rosuvastatin alone.	Rosuvastatin Calcium	184-196	nitric oxide synthase 3	Rattus norvegicus	56-60	
20940012-0	2011	eNOS/Hsp70 interaction on rosuvastatin cytoprotective effect in neonatal obstructive nephropathy.	Rosuvastatin Calcium	26-38	nitric oxide synthase 3	Rattus norvegicus	0-4	
22592772-8	2012	At the molecular level, rosuvastatin could inhibit the expression of ROCK-1 (P < 0.05, respectively) and PCNA (P < 0.01, respectively) but restore the expression of eNOS (P < 0.05, respectively).	Rosuvastatin Calcium	24-36	nitric oxide synthase 3	Rattus norvegicus	171-175	
22592772-11	2012	The effects of rosuvastatin seemed to be associated with the regulation of ROCK-1, PCNA, and eNOS expression.	Rosuvastatin Calcium	15-27	nitric oxide synthase 3	Rattus norvegicus	93-97	
21641341-4	2011	Rosuvastatin (5mg/kg, for 14 days and 28 days) treatment significantly attenuated monocrotaline-induced pulmonary vascular remodeling, right ventricular hypertrophy and dysfunction, and normalized the down-regulated pulmonary Akt/p-Akt and eNOS/p-eNOS expressions, while increased DDAH2 expression accompanied by decreased serum level of ADMA.	Rosuvastatin Calcium	0-12	nitric oxide synthase 3	Rattus norvegicus	240-244	
21641341-4	2011	Rosuvastatin (5mg/kg, for 14 days and 28 days) treatment significantly attenuated monocrotaline-induced pulmonary vascular remodeling, right ventricular hypertrophy and dysfunction, and normalized the down-regulated pulmonary Akt/p-Akt and eNOS/p-eNOS expressions, while increased DDAH2 expression accompanied by decreased serum level of ADMA.	Rosuvastatin Calcium	0-12	nitric oxide synthase 3	Rattus norvegicus	247-251	
21641341-6	2011	We concluded that rosuvastatin inhibits monocrotaline-induced pulmonary hypertension through normalization of Akt, eNOS and DDAH2 expressions, and decreasing the level of ADMA.	Rosuvastatin Calcium	18-30	nitric oxide synthase 3	Rattus norvegicus	115-119	
22683596-0	2012	Caveolin-1-eNOS/Hsp70 interactions mediate rosuvastatin antifibrotic effects in neonatal obstructive nephropathy.	Rosuvastatin Calcium	43-55	nitric oxide synthase 3	Rattus norvegicus	11-15	
22683596-4	2012	Here, we evaluated whether caveolin-1 associated with eNOS/Hsp70 expression may be involved in the mechanism by which rosuvastatin exerts tubulointerstitial fibrosis protection in neonatal unilateral ureteral obstruction (UUO).	Rosuvastatin Calcium	118-130	nitric oxide synthase 3	Rattus norvegicus	54-58	
22683596-7	2012	Conversely, rosuvastatin treatment attenuated the fibrotic response linked to high NO availability, decreased mRNA and protein caveolin-1 expression, and marked upregulation of eNOS and Hsp70 expression at transcriptional and posttranscriptional levels.	Rosuvastatin Calcium	12-24	nitric oxide synthase 3	Rattus norvegicus	177-181	
21641341-0	2011	Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism.	Rosuvastatin Calcium	0-12	nitric oxide synthase 3	Rattus norvegicus	91-95	
21641341-1	2011	This study was designed to investigate whether rosuvastatin could attenuate monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling pathway and asymmetric dimethylarginine (ADMA) metabolism in rats.	Rosuvastatin Calcium	47-59	nitric oxide synthase 3	Rattus norvegicus	143-147	
20940012-3	2011	Here we determined whether eNOS associated with Hsp70 expression is involved in rosuvastatin resistance to obstruction-induced oxidative stress and cell death.	Rosuvastatin Calcium	80-92	nitric oxide synthase 3	Rattus norvegicus	27-31	
20940012-7	2011	Conversely, in cortex membrane fractions from rosuvastatin-treated UUO rats, marked upregulation of eNOS expression at transcriptional and posttranscriptional levels linked to increased Hsf1 mRNA expression and enhanced mRNA and protein Hsp70 expression, were observed.	Rosuvastatin Calcium	46-58	nitric oxide synthase 3	Rattus norvegicus	100-104	
20940012-9	2011	In addition, interaction between eNOS and Hsp70 was determined by communoprecipitation in cortex membrane fractions, showing an increased ratio of both proteins, after rosuvastatin treatment in obstructed kidney.	Rosuvastatin Calcium	168-180	nitric oxide synthase 3	Rattus norvegicus	33-37	
20940012-10	2011	In summary, our data demonstrate that the effect of rosuvastatin on eNOS interacting with Hsp70, results in the capacity of both to prevent mitochondrial apoptotic pathway and oxidative stress in neonatal early kidney obstruction.	Rosuvastatin Calcium	52-64	nitric oxide synthase 3	Rattus norvegicus	68-72	
16610051-0	2006	Rosuvastatin reduces rat intestinal ischemia-reperfusion injury associated with the preservation of endothelial nitric oxide synthase protein.	Rosuvastatin Calcium	0-12	nitric oxide synthase 3	Rattus norvegicus	100-133	
16610051-12	2006	The mucosal protein levels of eNOS decreased during I-R, but were preserved in rats treated with rosuvastatin.	Rosuvastatin Calcium	97-109	nitric oxide synthase 3	Rattus norvegicus	30-34	
16610051-13	2006	CONCLUSION: Rosuvastatin inhibits rat intestinal injury and inflammation induced by I-R, and its protection is associated with the preservation of eNOS protein.	Rosuvastatin Calcium	12-24	nitric oxide synthase 3	Rattus norvegicus	147-151